Drug Profile


Alternative Names: Retroviral Expression Vectors Bearing Inhibitory Genes; Rexin-G; Targeted nanomedicine; Tumour-targeted gene therapy vector - Epeius

Latest Information Update: 29 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Epeius Biotechnologies
  • Developer Epeius Biotechnologies Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Solid tumours
  • Discontinued Breast cancer; Osteosarcoma; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 02 Jun 2010 Efficacy and adverse event data from the phase II portion of a phase I/II trial in chemotherapy-resistant bone and soft tissue sarcoma released by Epeius Biotechnologies
  • 24 May 2010 Efficacy and adverse events data from a phase I/II trial in Pancreatic cancer released by Epeius Biotechnologies
  • 24 May 2010 Pharmacodynamics data from a phase I/II trial in Cancer released by Epeius Biotechnologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top